hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06359080 id: 120200004OL briefTitle: Transcranial Photobiomodulation for Reducing Autism Symptoms in Children - Open Label Study (TPBMASDOL) overallStatus: COMPLETED date: 2022-05-08 date: 2022-12-11 date: 2022-12-11 date: 2024-04-11 date: 2024-04-11 name: JelikaLite LLC class: INDUSTRY briefSummary: The hypothesis of the study is that photobiomodulation reduces symptoms of autism. Participants will be children between the ages of 2 and 7, who have been diagnosed with moderate to severe autism. Transcranial photobiomodulation will be administered to the children in the experimental condition twice a week for 10 weeks. Results will be measured through parental interviews, standardized CARS2 (Childhood Autism Rating Scales, 2nd Edition) and data collected from EEG. conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Open Label Study
This will be an one-arm, open label study. Participants who were in the placebo condition in the previous study, will receive the treatment. Participants who were in the active condition in the previous study will repeat the course of treatment after the intermission of 3-6 months (depending on when they completed the study). primaryPurpose: TREATMENT masking: NONE count: 22 type: ACTUAL name: Cognilum TM: Light Treatment Condition measure: Change in Autism Symptoms sex: ALL minimumAge: 2 Years maximumAge: 7 Years stdAges: CHILD facility: Dr. Steingold Psychology PC city: Brooklyn state: New York zip: 11229 country: United States lat: 40.6501 lon: -73.94958 facility: Dr. Steingold Psychology PC city: New York state: New York zip: 10019 country: United States lat: 40.71427 lon: -74.00597 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2022-05-01 uploadDate: 2024-04-08T10:25 filename: Prot_000.pdf size: 332012 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2022-05-01 uploadDate: 2024-04-08T10:25 filename: SAP_001.pdf size: 134095 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2022-05-01 uploadDate: 2024-04-08T10:26 filename: ICF_002.pdf size: 172416 hasResults: False
nctId: NCT06359067 id: APHP240295 briefTitle: A Real-World Study of Bispecific Antibodies in Multiple Myeloma acronym: BISPEMM overallStatus: COMPLETED date: 2022-07-01 date: 2023-12-31 date: 2023-12-31 date: 2024-04-11 date: 2024-04-11 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for patients with multiple myeloma who are refractory to all current drugs. The results are very encouraging but complicated adverse events, particularly infectious. This study analyzes survival data in patients treated with BsAb, as well as safety data, in particular the proportions and locations of infectious events. The results are compared to a control cohort. This study is multicentric on all the university hospitals of Paris (AP-HP). conditions: Multiple Myeloma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 600 type: ACTUAL name: Treated by bispecific antibodies, teclistamab or elranatamab in usual care name: Not treated by bispecific antibodies in usual care measure: Infection rate measure: Global survival measure: Progression-free survivals sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Assistance Publique - Hôpitaux de Paris (AP-HP) city: Paris state: IDF zip: 75004 country: France lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06359054 id: CelalBayarNRG briefTitle: The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging overallStatus: COMPLETED date: 2020-11-11 date: 2023-05-15 date: 2023-09-15 date: 2024-04-11 date: 2024-04-11 name: Celal Bayar University class: OTHER briefSummary: Currently, F-18 FDG PET/CT is routinely used for breast cancer staging and treatment response assessment. Most breast cancers express Estrogen Receptor (ER) and Progesterone Receptor (PR) and this subtype shows lower activity on FDG imaging. 68Ga DOTATATE PET/CT is an effective imaging option for somatostatin receptor (SSTR) positive neuroendocrine tumors. There are case reports showing 68Ga DOTATATE uptake in non-Hodgkin lymphoma, meningioma, breast cancer, thyroid adenoma and papillary carcinoma. There are also histochemical studies showing that SSTR is a potential radiopharmaceutical target for ER+/PR+ breast cancer . Its hypothesized that 68Ga DOTATATE PET/CT may be superior to 18F FDG PET/CT primarily in hormone receptor (HR) positive breast cancer. In this study, its aimed to compare the uptake pattern of breast cancer lesions and HR status with 68Ga DOTATATE and 18F FDG uptake in lesions. conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 16 type: ACTUAL name: 18F FDG PET/CT name: 68Ga DOTATATE PET/CT measure: Comparative Diagnostic Accuracy of 68Ga DOTATATE and 18F FDG PET/CT sex: FEMALE minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Manisa Celal Bayar University Faculty of Medicine, General Surgery Department city: Manisa zip: 45030 country: Turkey lat: 38.61202 lon: 27.42647 facility: Manisa Celal Bayar University Faculty of Medicine, Nuclear Medicine Department city: Manisa zip: 45030 country: Turkey lat: 38.61202 lon: 27.42647 hasResults: False
nctId: NCT06359041 id: CAB-201-004 briefTitle: RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2029-09 date: 2029-09 date: 2024-04-11 date: 2024-04-25 name: Cabaletta Bio class: INDUSTRY briefSummary: RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis conditions: Generalized Myasthenia Gravis (gMG) studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: CABA-201 measure: To evaluate incidence and severity of adverse events (AEs) measure: To evaluate the incidence and severity of adverse events (AEs) measure: To characterize the pharmacodynamics (PD) measure: To characterize the pharmacokinetics (PK) measure: To evaluate disease-related biomarkers measure: To evaluate efficacy by change in Myasthenia Gravis - Activities of Daily Living (MG-ADL) score over time. measure: To evaluate efficacy by change in Quantitative Myasthenia Gravis (QMG) score over time. measure: To evaluate efficacy by change in Myasthenia Gravis Composite (MGC) score over time. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06359028 id: 300103 briefTitle: Clinical Study to Evaluate the Anti-sensitivity Efficacy of a Stannous Fluoride Toothpaste in a Population of Dentin Hypersensitivity Sufferers overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-25 date: 2024-06-20 date: 2024-06-20 date: 2024-04-11 date: 2024-04-25 name: HALEON class: INDUSTRY briefSummary: The aim of this study is to confirm the clinical Dentin Hypersensitivity (DH) efficacy of a 0.454 percent (%) Stannous Fluoride (SnF2) toothpaste. conditions: Dentin Sensitivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 111 type: ACTUAL name: Stannous fluoride toothpaste name: Crest cavity protection toothpaste measure: Change from Baseline in Schiff Sensitivity Score at Day 56 measure: Change from Baseline in Tactile Threshold at Day 56 measure: Change from Baseline in Schiff sensitivity score at Day 28 measure: Change from Baseline in Tactile Threshold at Day 28 measure: Change from Baseline in Impact on Everyday Life (Section 1 of Dentin Hypersensitivity Experience Questionnaire [DHEQ-48], Question [Q]7-9) at Days 28 and 56 measure: Change from Baseline in DHEQ Total Score (Section 2, Q1-34) at Days 28 and 56 measure: Change from Baseline in DHEQ Restrictions Domain (Section 2, Q1-4) Score at Days 28 and 56 measure: Change from Baseline in DHEQ Adaptation Domain Score (Section 2, Q5-16) at Days 28 and 56 measure: Change from Baseline in DHEQ Social Impact Domain (Section 2, Q17-21) Score at Days 28 and 56 measure: Change from Baseline in DHEQ Emotional Impact Domain (Section 2, Q22-29) Score at Days 28 and 56 measure: Change from Baseline in DHEQ Identity Domain (Section 2, Q30-34) Score at Days 28 and 56 measure: Change from Baseline in Global Oral Health (Section 2, Q35) Score at Days 28 and 56 measure: Change from Baseline in Effect on Life Overall (Section 2, Q36-39) Score at Days 28 and 56 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Salus Research city: Fort Wayne state: Indiana zip: 46825 country: United States lat: 41.1306 lon: -85.12886 hasResults: False
nctId: NCT06359015 id: 41138 id: 605095 type: OTHER domain: DDD briefTitle: Metformin and Esomeprazole in Preterm Pre-eclampsia overallStatus: ACTIVE_NOT_RECRUITING date: 2021-02-11 date: 2025-06 date: 2025-06 date: 2024-04-11 date: 2024-04-11 name: Christiana Care Health Services class: OTHER briefSummary: The purpose of this study is to better understand diagnosis and treatment of preterm preeclampsia. Currently, there are limited laboratory tests that can be used to diagnosis preeclampsia. Additionally, there are few treatments for this condition. This clinical trial will explore treatment options, Metformin and Esomeprazole, as well as serum markers that could improve the diagnosis and treatment of preterm preeclampsia. conditions: Preeclampsia Severe conditions: Pre-Eclampsia conditions: Preeclampsia conditions: Preeclampsia Second Trimester conditions: Preeclampsia Complicating Childbirth conditions: Preeclampsia Puerperium conditions: Preterm studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: There are two groups: experimental and control. The control group receives expectant management. The experimental group receives expectant management and medication treatment. primaryPurpose: TREATMENT masking: NONE count: 4 type: ACTUAL name: Metformin name: Esomeprazole measure: Mean plasma difference in sFlt-1 measure: Mean plasma difference in vascular endothelial growth factor (VEGF) measure: Mean plasma difference in placental growth factor (PIGF) measure: Mean plasma difference in soluble endoglin (sEng) measure: sFlt-1:PIGF ratio measure: Prolongation of gestation sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Christianacare Health System city: Newark state: Delaware zip: 19718 country: United States lat: 39.68372 lon: -75.74966 hasResults: False
nctId: NCT06359002 id: BYON4413.001 id: 2023-507781-13-00 type: CTIS briefTitle: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms. overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-12 date: 2027-03 date: 2024-04-11 date: 2024-04-11 name: Byondis B.V. class: INDUSTRY briefSummary: This is the first-in-human trial with BYON4413 to evaluate safety, PK, immunogenicity, and anti-leukemia activity of BYON4413 in patients with AML or MDS. conditions: Relapsed / Refractory AML conditions: Relapsed / Refractory MDS studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: BYON4413 measure: Incidence of dose-limiting toxicities (dose escalation) measure: Composite Complete Remission Rate (expansion) measure: Incidence and severity of adverse events measure: Number of patients with dose modifications measure: Rate of early death measure: Maximum Plasma Concentration (Cmax) BYON4413 measure: Time to Cmax (Tmax) BYON4413 measure: Area under the curve (AUC) BYON4413 measure: Percentage of patients with confirmed anti-BYON4413 antibodies measure: Composite Complete Remission Rate (dose escalation) measure: Percentage of blasts in bone marrow change from baseline measure: Percentage of blasts in peripheral blood change from baseline measure: Objective response rate measure: Duration of response measure: Relapse-free survival measure: Event-free survival measure: Time to response measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06358989 id: Insulin resistance briefTitle: Association Between Triglycerides Glucose Ratio With HOMA -IR as Indicators of Insulin Resistance in Obese Adults overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-05-01 date: 2024-04-11 date: 2024-04-11 name: Assiut University class: OTHER briefSummary: The aim of the present study was to investigate the correlation between the triglyceride/glucose index (TyG index) and homeostasic model assessment of insulin resistance (HOMA-IR) to predict insulin resistance (IR) in obese adults conditions: Insulin Resistance studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED name: HOMA IR measure: Association between triglycerides glucose ratio with HOMA -IR as indicators of insulin resistance in obese adults sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06358976 id: Spasticity splint and FMV briefTitle: Anti-Spastic Splint With Focal Muscle Vibration for Stroke Hand Spasticity overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2024-11-30 date: 2024-12-30 date: 2024-04-11 date: 2024-04-15 name: Arab American University (Palestine) class: OTHER briefSummary: Title: The Effect of Vibrating Splint on Hand Function After Stroke
This research is essential as it addresses the need for more effective interventions for spasticity management and hand rehabilitation after stroke. By providing valuable insights into the potential benefits of the vibrating splint, this study has the potential to improve the quality of life for individuals who have experienced a stroke and empower them to regain control over their hand movements. conditions: Spasticity as Sequela of Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: The interventional study model for this clinical study is a pilot randomized controlled trial. Participants will be randomly assigned to one of three arms: Group A (vibrating splint intervention), Group B (standard splint intervention), or Group C (control group receiving no splint intervention). This model allows for the comparison of different interventions and the evaluation of their effectiveness in improving hand function and reducing spasticity after stroke. Randomization helps ensure that each group is comparable in terms of baseline characteristics, minimizing bias and increasing the validity of the study results. primaryPurpose: OTHER masking: SINGLE maskingDescription: In this clinical trial, due to the nature of the interventions, it may not be possible to mask or blind the participants or therapists to the treatment received. However, efforts will be made to blind the outcome assessors who will be responsible for evaluating the participants' hand function, spasticity, and other outcome measures. Blinding the outcome assessors helps minimize potential bias and ensures the objective assessment of the intervention's effectiveness. By keeping the assessors unaware of the participants' group allocations, the integrity and reliability of the study findings can be enhanced. whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: Vibration plus anti-spastic hand splint name: Anti-spastic hand splint name: Vibration measure: Modified Ashworth Scale (MAS) measure: Fugl-Meyer Assessment of Upper Extremity (FMA-UE) measure: Range of Motion Assessment measure: Numeric pain rating scale (NRS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Arab American University city: Jenin zip: 240 country: Palestinian Territory, occupied name: Hisham Arab Alkabeya, PhD role: CONTACT phone: 0595637776 email: hisham.arabkkabeya@aaup.edu lat: 32.45943 lon: 35.30086 hasResults: False
nctId: NCT06358963 id: 131 briefTitle: CoQ10 and Omega-3 as Adjuncts to Periodontal Therapy, TAC of Saliva. overallStatus: ENROLLING_BY_INVITATION date: 2024-02-20 date: 2024-04-20 date: 2024-05-10 date: 2024-04-11 date: 2024-04-17 name: Amirhossein Farahmand class: OTHER briefSummary: Comparative evaluation of CoQ10 and Omega-3 as adjuncts to periodontal therapy and total antioxidant capacity of saliva (randomized Double-Blind Clinicalials) conditions: Periodontal Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, Double-blind, Controlled design. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: The research was conducted using a double-blind methodology. To ensure impartiality, both the omega-3, Coq10, and control groups were given medications that had identical appearance, packaging, and color. To further eliminate bias, a clinician who had no involvement in the study labeled teh medications as A, B, and C (empty) based on their content, and distributed them among teh patients. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Receive 30 mg of Coq10 name: Non-Medicare Drugs measure: reduction of bleeding on probing measure: total Antioxidant capacity of saliva sex: ALL minimumAge: 28 Years maximumAge: 35 Years stdAges: ADULT facility: Amirhossein Farahmand city: Tehran zip: 1947833113 country: Iran, Islamic Republic of lat: 35.69439 lon: 51.42151 hasResults: False
nctId: NCT06358950 id: ALKS 2860-201 briefTitle: A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 acronym: Vibrance-1 overallStatus: RECRUITING date: 2024-03-28 date: 2025-07 date: 2025-07 date: 2024-04-11 date: 2024-04-11 name: Alkermes, Inc. class: INDUSTRY briefSummary: The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone. conditions: Narcolepsy Type 1 studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: ALKS 2680 name: Placebo measure: Change in Mean Sleep Latency (MSL) on the Maintenance of Wakefulness Test (MWT) from baseline to Week 6 measure: Change in Epworth Sleepiness Scale (ESS) from baseline to Week 6 measure: Mean weekly cataplexy rate (WCR) as derived by subject cataplexy measure: Incidence of adverse events sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Alkermes Investigational Site status: RECRUITING city: Huntersville state: North Carolina zip: 28708 country: United States lat: 35.41069 lon: -80.84285 hasResults: False
nctId: NCT06358937 id: #7/2023 briefTitle: Clinical and Microbiological Evaluation of Laser Assisted New Attachment Procedure (LANAP) Using Nd:Yag vs. Diode Laser in the Management Of Stage II Periodontitis overallStatus: RECRUITING date: 2023-11-01 date: 2024-05 date: 2024-05 date: 2024-04-11 date: 2024-04-11 name: Mahmoud Salem class: OTHER briefSummary: The aim of the present study is to compare the efficacy of LANAP to conventional scaling and root planing in the management of stage II periodontitis. conditions: Periodontal Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 27 type: ESTIMATED name: Laser Assisted New Attachment Procedure using ND:YAG laser name: Laser Assisted New Attachment Procedure using diode laser name: Scaling and Root Planing using ultrasonic and curettes measure: Microbiological assessment of Fusobacterium nucleatum measure: Microbiological assessment of Porphyromonas gingivalis measure: Microbiological assessment of Tannerella forsythia measure: Gingival index measure: Plaque index measure: Clinical attachment loss measure: Probing depth sex: ALL minimumAge: 30 Years maximumAge: 50 Years stdAges: ADULT facility: Faculty of Dentistry, Alexandria University status: RECRUITING city: Alexandria country: Egypt name: Mahmoud Salem, BDS role: CONTACT phone: 111 144 7745 phoneExt: +20 email: Masalem30192@gmail.com lat: 31.21564 lon: 29.95527 hasResults: False
nctId: NCT06358924 id: FDASU-RecID032004 briefTitle: Effect of Different Desensitizing Agents on Post-bleaching Hypersensitivity and Shade Stability overallStatus: COMPLETED date: 2021-11-13 date: 2023-08-25 date: 2023-09-20 date: 2024-04-11 date: 2024-04-23 name: Ain Shams University class: OTHER briefSummary: This study compared the effect of four different desensitizing agents on shade stability and dental hypersensitivity following dental bleaching procedure. The follow-up periods ranged from 24 hours to 1 year. conditions: Tooth Hypersensitivity studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This clinical study was conducted to evaluate the effect of using different desensitizing agents:
2. Post-bleaching long-term shade stability. primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: This clinical trial was double blinded trial in which both the participant and outcome assessor were blinded to allocation, thus the participant was unaware of which experimental material had been assigned to him/her. Also the outcome assessors were blinded to the treatment that each participant had received. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 48 type: ACTUAL name: Potassium nitrate with fluoride name: Casein phosphopeptide-amorphous calcium phosphate with fluoride name: Hydroxyapatite with fluoride name: PAMAM-carboxylic acid dendrimer measure: Post-bleaching hypersensitivity measure: Shade stability sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Faculty of Dentistry, Ain Shams University city: Cairo state: El Weilli zip: 4393005 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06358911 id: FDASU-RecID022001 briefTitle: A Clinical Study for the Effect of 4th Generation Poly AmidoAmine Dendrimer on Post-Bleaching Hypersensitivity and Shade Stability overallStatus: COMPLETED date: 2021-11-13 date: 2023-08-05 date: 2023-09-10 date: 2024-04-11 date: 2024-04-23 name: Ain Shams University class: OTHER briefSummary: This study assessed the impact of four desensitizing agents on both color stability and dental sensitivity following a bleaching procedure, spanning from the 24-hour to the 1-year follow-up assessment periods. conditions: Tooth Hypersensitivity studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This clinical study will be conducted to evaluate the effect of using 4th generation Poly amido amine dendrimer (PAMAM-COOH) as a desensitizing agent and compared with three different commercially available desensitizing materials: 3% potassium nitrate and 0.11% fluoride (Ultra EZ), as described by manufacturer, Casein-phosphopeptide-amorphous calcium phosphate with F, (MI paste plusTm), and Hydroxyapatite, Fluoride and Xylitol, Hydroxyapatite and F (ReminPro), on: